APA (7th ed.) Citation

KJ, N., F, M., EC, S., AF, W., D, P., R, C., . . . R, P. (2020). Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(16), 4280. https://doi.org/10.1158/1078-0432.CCR-20-0834

Chicago Style (17th ed.) Citation

KJ, Norsworthy, et al. "Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 26, no. 16 (2020): 4280. https://doi.org/10.1158/1078-0432.CCR-20-0834.

MLA (9th ed.) Citation

KJ, Norsworthy, et al. "Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 26, no. 16, 2020, p. 4280, https://doi.org/10.1158/1078-0432.CCR-20-0834.